- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02809001
The Effects of Autologous Fat Transfer on Preventing Expanded Skin From Expansion Failure
Study Overview
Detailed Description
The repair of skin defects is a common problem for reconstructive surgeons.Soft tissue expansion is a widely used technique for the repair of skin defects. Early expansion-related complications such as skin thinning, telangiectasia, and striae may result in expansion failure and ultimately jeopardize final outcome. In the past years, discontinuation of the expansion procedure was the only therapeutic option, when early alarm signs such as semitransparent appearance and telangiectasia of the expanded skin were encountered. We aimed to overcome these complications by therapeutic fat grafting to prevent skin necrosis and enable continuation of the expansion procedure.
Patients undergoing soft tissue expansion treatment for resurfacing skin lesions including scars and nevi that required therapeutic intervention due to early complication signs were included in this study. Patients were randomly divided into treatment group using autologous fat grafting and control group with discontinued expansion and expectant management. The treatment group received autologous fat transfer to the expanded skin.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Shanghai, China
- Shanghai Ninth People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Expanding skin donor site at the face, neck, anterior chest wall, abdominal wall or back;
- Implanted silicone expander of 50 to 800 ml in size;
- History of deterioration in the expanded skin texture that did not improve after the inflation procedure was suspended for more than 2 weeks;
- Persistent high level of expander internal pressure;
- Need for further skin expansion;
Exclusion Criteria:
- Evidence of infection, ischemia, ulcer or other pathological changes within the targeting area which defined as not suitable for expansion; or history of delayed healing, radiational therapy;
- Rupture of expanded skin, expander exposure;
- Significant renal, cardiovascular, hepatic and psychiatric diseases;
- Significant medical diseases or infection (including but not limited to the carrier of hepatitis B virus or HIV);
- BMI less than 17 or insufficient subcutaneous fat;
- History of any hematological disease, including leukopenia , thrombocytopenia, or thrombocytosis;
- History of allogenic bone marrow transplantation;
- Pregnant or lactating woman;
- Long history of smoking;
- Evidence of malignant diseases or unwillingness to participate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: Fat grafting
Autologous fat graft transplantation subdermally to expanded skin.
|
In the experimental group, liposuction will be performed and autologous fat graft will be harvest after washing with saline.
Patients will receive autologous fat graft transplantation subdermally to expanded skin.
|
No Intervention: Control
Expansion was discontinued until the early signs of complication disappeared.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To Measure the Change in Expansion Volume
Time Frame: Change from baseline volume at 12 weeks
|
Record the volume(ml) of each expander
|
Change from baseline volume at 12 weeks
|
To Measure the Change in Skin Thickness
Time Frame: Change from baseline skin thickness at 12 weeks
|
Record the thickness of the expanded skin(cm) by ultrasound scanning
|
Change from baseline skin thickness at 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To Measure the Texture of Expanded Flap with VISIA scanner
Time Frame: baseline and 12 weeks post treatment
|
Evaluate skin texture with VISIA scanner and compare the characteristics
|
baseline and 12 weeks post treatment
|
Occurence of Major Adverse Events
Time Frame: Up to approximately 12 weeks after study start
|
Including expanded flap ischaemia, necrosis, fluidify, infection, and all other adverse events
|
Up to approximately 12 weeks after study start
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Shanghai9PH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nevus
-
Massachusetts General HospitalNot yet recruitingCongenital Melanocytic Nevus
-
University of California, DavisRecruiting
-
Mahidol UniversityUnknownFocus on Laser Treatment of Nevus of Ota in Thai PatientsThailand
-
University of California, IrvineBeckman Laser Institute University of California IrvineWithdrawnMelanocytic NevusUnited States
-
Medical University of GrazCompleted
-
University Hospital, Basel, SwitzerlandCompleted
-
Istanbul Training and Research HospitalCompletedNevus, PigmentedTurkey
-
Manchester University NHS Foundation TrustNational Institute for Health Research, United KingdomCompleted
-
Albert ChiouNFlection Therapeutics, Inc.Not yet recruitingEpidermal Nevi | Nevus SebaceusUnited States
-
Russian Academy of Medical SciencesBlokhin's Russian Cancer Research CenterRecruitingMelanoma | Nevus | Nevus, Pigmented | Melanoma (Skin) | Mucosal Melanoma | Moles | Dysplastic Nevus Syndrome | Nevus, Blue | Nevus, Spitz | Nevi, Spindle Cell | Nevi, Dysplastic | Mucosal MelanosisRussian Federation
Clinical Trials on Fat grafting
-
Lawson Health Research InstituteNot yet recruitingBreast Asymmetry | Fat Atrophy
-
University College, LondonCompletedDiabetes Mellitus Foot UlcerUnited Kingdom
-
Melanie Salerno, RNLifespanUnknown
-
University of Texas Southwestern Medical CenterCompletedAcne Scars - Mixed Atrophic and Hypertrophic | AcneUnited States
-
University of PittsburghCompleted
-
University of PittsburghUnited States Department of DefenseCompletedFacial Injuries | Adipose TissueUnited States
-
Odense University HospitalCompletedHerpes Zoster | Post Herpetic NeuralgiaDenmark
-
Mayo ClinicWithdrawnBreast CancerUnited States
-
Mayo ClinicEnrolling by invitationBreast Reconstruction | Radiation Dermatitis | Radiation Fibrosis | Fat GraftingUnited States
-
University of PittsburghUnited States Department of DefenseTerminatedCraniofacial InjuriesUnited States